1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Takeda/Protagonist’s Rusfertide Could Be A Main Character In PV After Phase III Data

 
• By Alaric DeArment

The companies announced positive data from the VERIFY study among patients with PV, showing lower proportions of patients requiring phlebotomy.

Concept of blood cells count, medicine and healthcare. 3d rendering mock up
(Shutterstock)

Takeda Pharmaceutical envisions a potentially significant market in polycythemia vera (PV) for rusfertide, which it is developing together with Protagonist Therapeutics, after reporting positive Phase III data for the drug. Rusfertide particularly stands to benefit from the more than three-quarters of patients with PV who have uncontrolled hematocrit levels.

The two companies announced positive data on 3 March from the VERIFY study comparing rusfertide against placebo as an add-on to standard-of-care treatment in patients with PV who were dependent...

Key Takeaways
  • VERIFY hit its phlebotomy primary endpoint of absence of phlebotomy eligibility, as well as the secondary endpoint of mean number of phlebotomies per patient, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.